초록 ▼

A glass-breakage detector that provides improved immunity to false triggering when detecting the breakage of a glass window, or similar structure, as sensed by an acoustic transducer. The detector employs a validation method which improves discrimination of commonly known false alarm signals, such a

A glass-breakage detector that provides improved immunity to false triggering when detecting the breakage of a glass window, or similar structure, as sensed by an acoustic transducer. The detector employs a validation method which improves discrimination of commonly known false alarm signals, such as glass flexing. Signals from an acoustic transducer are amplified, conditioned, and measured within three signal processing sections which process the signals at low-frequencies, medium-frequencies, and high-frequencies according to methods highly selective to breakage events. The detector provides an alarm output upon validating a detected breakage event.

대표청구항 ▼

A glass-breakage detector that provides improved immunity to false triggering when detecting the breakage of a glass window, or similar structure, as sensed by an acoustic transducer. The detector employs a validation method which improves discrimination of commonly known false alarm signals, such a

A glass-breakage detector that provides improved immunity to false triggering when detecting the breakage of a glass window, or similar structure, as sensed by an acoustic transducer. The detector employs a validation method which improves discrimination of commonly known false alarm signals, such as glass flexing. Signals from an acoustic transducer are amplified, conditioned, and measured within three signal processing sections which process the signals at low-frequencies, medium-frequencies, and high-frequencies according to methods highly selective to breakage events. The detector provides an alarm output upon validating a detected breakage event. composition comprising as the active ingredient a phenoxyacetic acid derivative as claimed in claim 1, or a pharmaceutically acceptable salt thereof. 5. An agent for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract, which comprises as the active ingredient a phenoxyacetic acid derivative as claimed in claim 1, or a pharmaceutically acceptable salt thereof. 6. A method for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract, which comprises administering a therapeutically effective amount of a phenoxyacetic acid derivative as claimed in claim 1, or a pharmaceutically acceptable salt thereof. 7. A pharmaceutical composition comprising as the active ingredient a phenoxyacetic acid derivative as claimed in claim 2, or a pharmaceutically acceptable salt thereof. 8. An agent for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract, which comprises as the active ingredient a phenoxyacetic acid derivative as claimed in claim 2, or a pharmaceutically acceptable salt thereof. 9. A method for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract, which comprises administering a therapeutically effective amount of a phenoxyacetic acid derivative as claimed in claim 2, or a pharmaceutically acceptable salt thereof. 10. A pharmaceutical composition comprising as the active ingredient a phenoxyacetic acid derivative as claimed in claim 3, or a pharmaceutically acceptable salt thereof. 11. An agent for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract, which comprises as the active ingredient a phenoxyacetic acid derivative as claimed in claim 3, or a pharmaceutically acceptable salt thereof. 12. A method for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract, which comprises administering a therapeutically effective amount of a phenoxyacetic acid derivative as claimed in claim 3, or a pharmaceutically acceptable salt thereof. Theorie der Perkin'schen Synthese Uber den Mechanismus der Reaktion". Org. Reactions I, (month unavailable) 1942, pp. 210-265, John R. Johnson, "The Perkin Reaction & Related Reactions". Claisen-Schmidt Reaction; (Ber. 23,) (month unavailable) 1890, pp. 976-978, L. Claisen, "Zur Darstellung der Zimmtsaure und ihrer Homologen".